

> CARDIOLOGY


# FORMULAE AND QUICK REFERENCE

CARDIOLOGY

![](https://i.imgur.com/QgkgD06.jpg)

“Rule of 6s” for PAC: RA ≤6, RV ≤30/6, PA ≤30/12, WP ≤12. Nb 1 mmHg = 1.36 cm water or blood.

Fick cardiac output

Oxygen consumption (L/min) = CO (L/min) × arteriovenous (AV) oxygen difference

CO = oxygen consumption/AV oxygen difference

Oxygen consumption must be measured (can estimate with 125 mL/min/m2, but inaccurate)

AV oxygen difference = Hb (g/dL) × 10 (dL/L) × 1.36 (mL O2/g of Hb) × (SaO2–SMVO2)

SaO2 is measured in any arterial sample (usually 93–98%)

SMVO2 (mixed venous O2) is measured in RA, RV, or PA (assuming no shunt) (nl ~75%)

![](https://i.imgur.com/DoRaX4H.jpg)

### Assessment of RV function (_Circ_ 2017;136:314)

PAPi = Pulmonary artery pulsatility index = \[PA systolic – PA diastolic\] / RA pressure >1.0 predicts RV failure in acute MI; <1.85 predicts RV failure after LVAD

### Shunts

![](https://i.imgur.com/hgML8sJ.jpg)

### Valve equations

Simplified Bernoulli: Pressure gradient (∇P) = 4 × v2 (where v = peak flow velocity)

Continuity (conservation of flow): Area1 × Velocity1 = A2 × V2 (where 1 & 2 different points)

![](https://i.imgur.com/jTaM1LH.jpg)

![](https://i.imgur.com/73Qhpod.jpg)

PULMONARY

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p>Chest Imaging (CXR &amp; CT) Patterns</p></td></tr><tr><td><p>Pattern</p></td><td><p>病生理</p></td><td><p>Ddx</p></td></tr><tr><td><p>Consolidation</p></td><td><p>Radiopaque material in air space &amp; interstitium patent airway → “air bronchograms”</p></td><td><p><i>Acute:</i> water <b>(pulm edema)</b>, pus <b>(PNA)</b>, <b>blood</b></p><p><i>Chronic:</i> neoplasm (BAC, lymphoma), aspiration, inflammatory (COP, eosinophilic PNA), PAP, granuloma (TB/fungal, alveolar sarcoid)</p></td></tr><tr><td><p>Ground glass (CT easier than CXR)</p></td><td><p>Interstitial thickening or partial filling of alveoli (but vessels visible)</p></td><td><p><i>Acute:</i> pulm edema, infxn (PCP, viral, resolving bact. PNA)</p><p><i>Chronic:</i> ILD</p><p>w/o fibrosis: acute hypersens., DIP/RB, PAP with fibrosis: IPF</p></td></tr><tr><td><p>Septal lines Kerley A &amp; B</p></td><td><p>Radiopaque material in septae</p></td><td><p><b>Cardiogenic pulm edema</b>, interstitial PNA viral, mycoplasma, lymphangitic tumor</p></td></tr><tr><td><p>Reticular</p></td><td><p>Lace-like net (ILD)</p></td><td><p><b>ILD</b> (esp. IPF, CVD, bleomycin, asbestos)</p></td></tr><tr><td><p>Nodules</p></td><td><p>Tumor</p><p>Granulomas</p><p>Abscess</p></td><td><p><i>Cavitary:</i> <b>Primary or metastatic cancer</b>, <b>TB</b> (react. or miliary), <b>fungus</b>, Wegener’s, RA <b>septic emboli</b>, PNA</p><p><i>Noncavitary:</i> any of above + <b>sarcoid</b>, hypersens. pneum., HIV, Kaposi’s sarcoma</p></td></tr><tr><td><p>Wedge opac.</p></td><td><p>Peripheral infarct</p></td><td><p><b>PE</b>, cocaine, angioinv. aspergillus, Wegener’s</p></td></tr><tr><td><p>Tree-in-bud (best on CT)</p></td><td><p>Inflammation of small airways</p></td><td><p><b>Bronchopneumonia</b>, endobronchial TB/MAI, viral PNA, aspiration, ABPA, CF, asthma, COP</p></td></tr><tr><td><p>Hilar fullness</p></td><td><p>↑ LN or pulm arteries</p></td><td><p><b>Neoplasm</b> (lung, mets, lymphoma)</p><p><b>Infxn</b> (AIDS); <b>Granuloma</b> (sarcoid/TB/fungal)</p><p>Pulmonary hypertension</p></td></tr><tr><td><p>Upper lobe</p></td><td><p>n/a</p></td><td><p><b>TB</b>, fungal, sarcoid, hypersens. pneum., CF, XRT</p></td></tr><tr><td><p>Lower lobe</p></td><td><p>n/a</p></td><td><p><b>Aspiration</b>, bronchiect., IPF, RA, SLE, asbestos</p></td></tr><tr><td><p>Peripheral</p></td><td><p>n/a</p></td><td><p>COP, IPF &amp; DIP, eos PNA, asbestosis</p></td></tr></tbody></table>

### CXR in heart failure

• ↑ cardiac silhouette (in systolic dysfxn, not in diastolic)

• Pulmonary venous hypertension: cephalization of vessels (vessels size > bronchi in upper lobes), peribronchial cuffing (fluid around bronchi seen on end → small circles), Kerley B lines (horizontal 1–2-cm lines at bases), ↑ vascular pedicle width, loss of sharp vascular margins, pleural effusions (~75% bilateral)

• Pulmonary edema: ranges from ground glass to consolidation; often dependent and central, sparing outer third (“bat wing” appearance)

### Dead space = lung units that are ventilated but not perfused

### Intrapulmonary shunt = lung units that are perfused but not ventilated

![](https://i.imgur.com/Nd6PSde.jpg)

### A-a gradient = PAO2 – PaO2 \[normal A-a gradient ≈ 4 + (age/4)\]

### Minute ventilation (VE) = tidal volume (VT) × respiratory rate (RR)(nl 4–6 L/min)

### Tidal volume (VT) = alveolar space (VA) + dead space (VD)

![](https://i.imgur.com/ER3PFE6.jpg)

GASTROENTEROLOGY

![](https://i.imgur.com/raVlmti.jpg)

NEPHROLOGY

### Anion gap (AG) = Na – (Cl + HCO3) (normal = \[alb\] × 2.5; typically 12 ± 2 mEq)

### Delta-delta (ΔΔ) = \[Δ AG (ie, calc. AG – expected) / Δ HCO3 (ie, 24 – measured HCO3)\]

### Urine anion gap (UAG) = (UNa + UK) – UCl

![](https://i.imgur.com/J0xunlO.jpg)

However, Δ in Na depends on glc (_Am J Med_ 1999;106:399)

Δ is 1.6 mEq per each 100 mg/dL ↑ in glc ranging from 100–440

Δ is 4 mEq per each 100 mg/dL ↑ in glc beyond 440

### Total body water (TBW) = 0.60 × IBW (× 0.85 if female and × 0.85 if elderly)

![](https://i.imgur.com/kGt60P5.jpg)

### Trans-tubular potassium gradient (TTKG) = \[UK / PK\] / \[UOsm / POsm\]

HEMATOLOGY

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p>Peripheral Smear Findings <span>(also see Photo Inserts)</span></p></td></tr><tr><td><p>Feature</p></td><td><p>Abnormalities and Diagnoses</p></td></tr><tr><td><p><b>Size</b></p></td><td><p>normocytic vs. microcytic vs. macrocytic → see below</p></td></tr><tr><td><p><b>Shape</b></p></td><td><p><b>Anisocytosis</b> → unequal RBC size; <b>poikilocytosis</b> → irregular RBC shape acanthocytes = <b>spur</b> cells (irregular sharp projections) → liver disease</p><p><b>Bite</b> cells (removal of Heinz bodies by phagocytes) → G6PD deficiency echinocytes = <b>burr</b> cells (even, regular projections) → uremia, artifact</p><p><b>Pencil cell</b> → long, thin, hypochromic - very common in adv. iron deficiency</p><p><b>Rouleaux</b> → hyperglobulinemia (eg, multiple myeloma)</p><p><b>Schistocytes</b>, helmet cells → MAHA (eg, DIC, TTP/HUS), mechanical valve</p><p><b>Spherocytes</b> → HS, AIHA; <b>sickle</b> cells → sickle cell anemia</p><p><b>Stomatocyte</b> → central pallor appears as curved slit → liver disease, EtOH</p><p><b>Target</b> cells → liver disease, hemoglobinopathies, splenectomy</p><p><b>Tear drop</b> cells = dacryocytes → myelofibrosis, myelophthisic anemia, megaloblastic anemia, thalassemia</p></td></tr><tr><td><a id="page_11-8"></a><p><b>Intra- RBC findings</b></p></td><td><p><b>Basophilic stippling</b> (ribosomes) → 異常 Hb, sideroblastic, megaloblastic</p><p><b>Heinz bodies</b> (denatured Hb) → G6PD deficiency, thalassemia</p><p><b>Howell-Jolly bodies</b> (nuclear fragments) → splenectomy or functional asplenia (eg, advanced sickle cell)</p><p><b>Nucleated</b> RBCs → hemolysis, extramedullary hematopoiesis</p></td></tr><tr><td><p><b>WBC findings</b></p></td><td><p><b>Blasts</b> → leukemia, lymphoma; <b>Auer rods</b> → acute myelogenous leukemia</p><p><b>Hypersegmented</b> (&gt;5 lobes) PMNs: megaloblastic anemia (B<sub>12</sub>/folate def.)</p><p><b>Pseudo-Pelger-Huët anomaly</b> (bilobed nucleus, “pince-nez”) → MDS</p><p><b>Toxic granules</b> (coarse, dark blue) and <b>Döhle bodies</b> (blue patches of dilated endoplasmic reticulum) → (sepsis, severe inflammation)</p></td></tr><tr><td><p><b>Platelet</b></p></td><td><p><b>Clumping</b> → artifact, repeat plt count</p><p><b>#</b> → periph blood plt count ~10,000 plt for every 1 plt seen at hpf (100×)</p><p><b>Size</b> → MPV (mean platelet volume) enlarged in ITP</p></td></tr></tbody></table>

(_NEJM_ 2005;353:498)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p>Heparin for Thromboembolism</p></td></tr><tr><td colspan="2"><p>80 U/kg bolus</p><p>18 U/kg/h</p></td></tr><tr><td><p>PTT</p></td><td><p>Adjustment</p></td></tr><tr><td><p>&lt;40</p></td><td><p>bolus 5000 U, ↑ rate 300 U/h</p></td></tr><tr><td><p>40–49</p></td><td><p>bolus 3000 U, ↑ rate 200 U/h</p></td></tr><tr><td><p>50–59</p></td><td><p>↑ rate 150 U/h</p></td></tr><tr><td><p>60–85</p></td><td><p>no Δ</p></td></tr><tr><td><p>86–95</p></td><td><p>↓ rate 100 U/h</p></td></tr><tr><td><p>96–120</p></td><td><p>hold 30 min, ↓ rate 100 U/h</p></td></tr><tr><td><p>&gt;120</p></td><td><p>hold 60 min, ↓ rate 150 U/h</p></td></tr></tbody></table>

(Modified from _Chest_ 2008;133:141S)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p>Heparin for ACS</p></td></tr><tr><td colspan="2"><p>60 U/kg bolus (max 4000 U)</p><p>12 U/kg/h (max 1000 U/h)</p></td></tr><tr><td><p>PTT</p></td><td><p>Adjustment</p></td></tr><tr><td><p>&lt;40</p></td><td><p>bolus 3000 U, ↑ rate 100 U/h</p></td></tr><tr><td><p>40–49</p></td><td><p>↑ rate 100 U/h</p></td></tr><tr><td><p>50–75</p></td><td><p>no Δ</p></td></tr><tr><td><p>76–85</p></td><td><p>↓ rate 100 U/h</p></td></tr><tr><td><p>86–100</p></td><td><p>hold 30 min, ↓ rate 100 U/h</p></td></tr><tr><td><p>&gt;100</p></td><td><p>hold 60 min, ↓ rate 200 U/h</p></td></tr></tbody></table>

(Modified from _Circ_ 2007;116:e148 & _Chest_ 2008;133:670)

✔ PTT q6h after every Δ (t½ of heparin ~90 min) and then qd or bid once PTT is therapeutic

✔ CBC qd (to ensure Hct and plt counts are stable)

![](https://i.imgur.com/IQkVesa.jpg)

(_Annals_ 1997;126:133; _Archives_ 1999;159:46) or, go to [www.warfarindosing.org](http://www.warfarindosing.org/)

### Warfarin-heparin overlap therapy

• Indications: when failure to anticoagulate carries ↑ risk of morbidity or mortality (eg, DVT/PE, intracardiac thrombus)

• Rationale: (1) Half-life of factor VII (3–6 h) is shorter than half-life of factor II (60–72 h);

∴ warfarin can elevate PT _before achieving a true antithrombotic state_

(2) Protein C also has half-life less than that of factor II;

∴ theoretical concern of _hypercoagulable state_ before antithrombotic state

• Method: (1) Therapeutic PTT is achieved using heparin

(2) Warfarin therapy is initiated

(3) Heparin continued until INR therapeutic for ≥2 d and ≥4–5 d of warfarin (roughly corresponds to ~2 half-lives of factor II or a reduction to ~25%)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p>Common Warfarin-Drug Interactions</p></td></tr><tr><td><p>Drugs that ↑ PT</p></td><td><p>Drugs that ↓ PT</p></td></tr><tr><td><p>Amiodarone</p><p>Antimicrobials: erythromycin, ? clarithro, ciprofloxacin, MNZ, sulfonamides</p><p>Antifungals: azoles</p><p>Acetaminophen, cimetidine, levothyroxine</p></td><td><p>Antimicrobials: rifampin</p><p>CNS: barbiturates, carbamazepine, phenytoin (initial transient ↑ PT)</p><p>Cholestyramine</p></td></tr></tbody></table>

ENDOCRINOLOGY

![](https://i.imgur.com/bHEan8W.jpg)

![](https://i.imgur.com/qxmqk0p.jpg)

NEUROLOGY

![](https://i.imgur.com/pyBxvr6.jpg)

OTHER

![](https://i.imgur.com/NivBQBJ.jpg)
